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Estrogen is a steroid hormone that regulates embryogenesis, cell proliferation and diﬀerentiation, organogenesis, the timing of
parturition, and fetal imprinting by carrying chemical messages from glands to cells within tissues or organs in the body. During
development, placenta is the primary source of estrogen production but estrogen can only be produced if the fetus or the mother
supplies dehydroepiandrosterone (DHEA), the estrogen prohormone. Studies show that the fetal zone of the fetal adrenal cortex
supplies 60% of DHEA for placental estrogen production, and that placental estrogen in turn modulates the morphological
and functional development of the fetal adrenal cortex. As such, in developed countries where humans are exposed daily to
environmental estrogens, there is concern that the development of fetal adrenal cortex, and in turn, placental estrogen production
may be disrupted. This paper discusses fetal adrenal gland development, how endogenous estrogen regulates the structure and
function of the fetal adrenal cortex, and highlights the potential role that early life exposure to environmental estrogens may have
on the development and endocrinology of the fetal adrenal cortex.
1.Introduction
The fetal-origin hypothesis put forth by Dr. David Barker
nearly three decades ago challenged the traditional views on
the pathogenesis of common chronic diseases [1]. The Fetal-
OriginHypothesis,latertermedtheDevelopmentalOriginof
Health and Disease, established the principle that perinatal
events are memorized by the developing organism through
fetal and neonatal imprinting [2]. In light of this hypothesis,
perinatal events can be thought of as the foundation for
structural and functional development of an organism. All
organisms arise from a unique DNA sequence that gives rise
to specialized cell phenotypes through well-regulated gene
expression and epigenetic regulation [3]. Each cell phenoty-
pe can be inﬂuenced by its internal and external environ-
ment. In the human body, there are approximately 200 spe-
cialized cells that are inﬂuenced by internal and external ster-
oid hormones during development [3].
Steroid hormones act as chemical messengers to induce
both slow genomic and rapid nongenomic responses and,
thus, modulate a wide array of essential cellular and physi-
ological responses. In the initial stages of pregnancy, steroid
hormones send signals that allow the embryo to successfully
implant in the posterior wall of the uterus and regulate
cell proliferation, diﬀerentiation, and gene transcription. In
the later stages of gestation, steroid hormones support fetal
growth and development by modulating metabolic processes
of embryogenesis and organogenesis. Steroid hormones also
playapivotalroleinregulatingthetimingofparturition.Dif-
ferent steroid hormones are expressed at diﬀerent stages of
intrauterine life suggesting that temporal and spatial expres-
sion of steroid hormones is critical for fetal growth and de-
velopment [4, 5]. Of all the steroid hormones produced dur-
ing pregnancy, estrogen has attracted much interest because
itisexpressedateverystageofgestationandmodulatesmany
intrauterine processes.
Estrogen synthesis takes place in the ovaries, adrenal cor-
tex, and the placenta. During pregnancy, the placenta be-
comes the primary site of estrogen synthesis; however, plac-
ental estrogen production can only be achieved through2 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
Table 1: The eﬀects of estrogen on the mother and the fetus.
Estrogen in maternal circulation:
(i) Enhances myometrial activity
(ii) Soften collagen ﬁbers in the cervical tissue
(iii) Promotes myometrial vasodilation
(iv) Increases uterine blood ﬂow
(v) Increases production of insulin-like growth factors (IGF-I/II)
and binding proteins
(vi) Promotes growth of the uterus, vagina, and breast
(vii) Increases pituitary secretion of prolactin
(viii) Increases sensitivity of the maternal respiratory center to
carbon dioxide
(ix) Stimulates synthesis and turnover of phospholipids
(x) Increases serum binding proteins and ﬁbrinogens to decrease
plasma proteins
(xi) Increases the sensitivity of the uterus to progesterone in late
pregnancy
(xii) Helps to control behavior including fatique, forgetfulness,
poor concentration, as well as mild mood changes including
irritability and depressed mood
(xiii) Regulates salt and water retention
Estrogen in fetal circulation:
(i) Helps to maintain chemical levels in the bloodstream to achieve
intrauterine homeostasis, which is the state of stability within the
body
(ii) Promotes maturation of fetal organs
(iii) Regulates the fetal neuroendocrine system that controls
reaction to stress, digestion, immune function, mood and
emotion, sexuality, energy storage, and/or expenditure
(iv) Regulates timing of parturition
input from fetal and/or maternal adrenal cortex. This is
because of the placenta’s inability to produce the androgenic
C19 steroid (dehydroepiandrosterone, DHEA, and its sulfo-
conjuate, DHEA-S), the essential substrate for placental
estrogen [4, 6, 7]. The fetal adrenal gland provides a larger
proportion of the byproducts used for placental estrogen
production [8]. Appropriate development and function of
the fetal adrenal cortex is therefore critical for placental ster-
oid production (i.e., estrogen, cortisol, and aldosterone), fe-
tal maturation, and perinatal survival [9].
Emerging studies suggest that environmental estrogens
can disrupt the natural interplay between estrogen and func-
tionalbiologyofthefetaladrenalcortex[10,11].Humansare
exposed daily to environmental estrogens through the food
supply and the use of pesticides, herbicides, petroleum by-
products, and plastics. Some examples include soy isoﬂavo-
nes, bisphenol A, DDT, polychlorinated biphenyls, poly-
brominated diphenyl ethers, and a variety of phthalates.
Although environmental estrogens pose minimal threat to
adults,theymayhaveanadverseeﬀectonhumanhealthifex-
posure occurs during critical stages of development when
cells are more easily inﬂuenced by steroid hormones [2].
Most of the supporting studies in this area have focused on
a synthetic estrogen, diethylstilbestrol (DES). From about
1940–1970, DES was prescribed to pregnant women based
onthebeliefitcouldpreventmiscarriage(itisnolongerused
because of adverse eﬀects, particularly to oﬀspring). In vitro
assays have shown that compared to 17β-estradiol the estro-
genic potency of DES is 0.5 and that of all other environ-
mental estrogens listed previously is <0.0001 [12, 13]. Based
ontheestrogenicpotency,theadverseeﬀectsinducedbyDES
may be more severe than those induced by environmental
estrogens and thus have more subtle eﬀects that are non-
etheless disrupting placental estrogen production and fetal
development. This paper examines the available literature on
fetal adrenal gland development, how endogenous estrogen
regulates the structure and function of the fetal adrenal cor-
tex, and highlights the potential role that early life exposure
to environmental estrogens may have on the development
and endocrinology of the fetal adrenal cortex.
2. Estrogen Synthesisin Utero
Pioneering work by Edward Adelbert Doisy revealed that
three forms of estrogen (estradiol, estriol, estrone) are pre-
sent in the urine of pregnant women [15]. These three forms
of estrogen have also been detected in the fetal circulation
throughout gestation and in the umbilical cord plasma at
birth [16]. Concomitantly, the rate of estrogen production
and the amount of estrogen in the maternal and fetal plasma
increasesmarkedlythroughoutpregnancy.Byterm,estradiol
and estrone levels are 100-fold higher than those of nonpreg-
nant women and estriol levels are up to 1000-fold higher [8].
Although these high concentrations of estrogen are destined
for maternal compartments, they also induce a number of
biological eﬀects on the developing fetus (Table 1).
During early stages of pregnancy, estrogen is synthesized
by the corpus luteum in the maternal ovaries and its primary
function is to ensure that the mother does not reject the de-
veloping embryo. To accomplish this, estrogen enhances my-
ometrial activity, softens collagen ﬁbers in the cervical tissue,
and promotes vasodilation of the uterus. Around the 8th
week of gestation when the fetoplacental unit has a highly
vascularized network, placenta becomes the primary source
of estrogen production [4]. However, the production of
estrogen does not rely solely on the placenta. The placenta
convertsC19 steroidsintoestrogenbutcannotproduceestro-
gen de novo from acetate or cholesterol and cannot convert
pregnenolone or progesterone into C19 steroids because it
lacks the primary 17α-hydroxylase (P450c17) enzyme [4, 6,
7]. Estrogen synthesis by the primate placenta is therefore
achieved through stereogenic interplay between the ma-
ternal-placental unit and the fetal-placental unit (Figure 1).
In this system, the maternal-placental unit permits low-de-
nsity lipoproteins (LDLs) and/or free cholesterol to pass
through the placenta and enter the fetal circulation. The fetal
adrenal cortex, which expresses high amounts of P450c17
enzyme, has a highly developed ability to bind and use chol-
esterol to produce the DHEA and DHEA-S, which are the
essential substrates for placental estrogen production. Near
term, 60% of the total DHEA-S used by the placenta for
estradiol and estrone synthesis is derived from the fetalJ o u r n a lo fN u t r i t i o na n dM e t a b o l i s m 3
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Figure 1: The role of maternal, placental, and fetal units in the biosynthesis of estrone, estradiol, and estriol. (LDL: low-density lipoproteins;
DHEA-S: dehydroepiandrosterone sulfate; OH: hydroxyl). This ﬁgure has been modiﬁed from [8, 14].
adrenal cortex, whereas only 40% is derived from the ma-
ternal adrenal cortex [8]. The fetus, unlike the mother, also
produces 90% of 16α-hydroxyl DHEA-S, which is a substrate
for estriol synthesis. Therefore, the fetus rather than the
mother provides most of the byproducts used for placental
estrogen production [8].
3. Fetal AdrenalGlandDevelopment
Development of the fetal adrenal gland is a dynamic proc-
ess that is characterized by rapid cell growth, unique mor-
phological development, and high steroidogenic activity.
Throughoutgestation,thesizeandweightofthefetaladrenal
gland continuously grow but, unlike most other organs, the
adrenal gland regresses substantially from fetal to adult life
[17, 18]. At birth, the fetal adrenal gland weighs between
3a n d4g r a m sa n di s2 0t o3 0t i m e sl a r g e rt h a ni t sa d u l t
counterpart [17–20]. Moreover, its size at birth is approxi-
mately equal to that of the fetal kidney [4]. Studies focusing
on structural biology have revealed that the large size of
the fetal adrenal gland depends on a single structural com-
partment called the fetal zone (Figure 2), identiﬁed by Elliott
and Armour in 1911 [21]. The fetal zone occupies the
central region of the fetal adrenal cortex and by mid-gesta-
tion accounts for 80–90% of the fetal adrenal gland [17, 22].
Functionally, the fetal zone resembles the adult zona retic-
ulosa because it is the primary site of steroidogenesis [23].
Beginning around the 10th week of gestation, the fetal zone
expresses P450c17 enzyme and produces DHEA, the precur-
sor for placental estrogen production. Therefore, fetal zone
is the primary site of estrogen synthesis during gestation
Adrenal capsule
Adrenal cortex:
Deﬁnitive zone
Transitional zone
Fetal zone
Adrenal medulla
Figure 2: Illustration of the midgestation human fetal adrenal
gland.
[4]. Because placental estrogen production is exclusive to
intrauterine life, the fetal zone begins to regress at birth and
completely disappears in the ﬁrst few months of life. The de-
miseofthefetalzoneinducespostnatalremodelingandcaus-
es more than a 90% reduction in the adrenal gland size [23].
In addition to the fetal zone, the fetal adrenal cortex in
utero is composed of two other morphologically distinct
zones: the deﬁnitive zone and the transitional zone [9]. The
deﬁnitive zone, which is also called the neocortex, develops
as a narrow band of tightly packed cells surrounding the fe-
tal zone. It expresses the enzyme 3β-hydroxysteroid dehy-
drogenase (3β-HSD) that produces aldosterone. Thus, it is
believed to be the site that gives rise to the postnatal adrenal
glomerulosa [23, 24]. The third zone, the transitional zone,
develops in late gestation between the fetal and deﬁnitive4 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
zone and gives rise to zona fascicularis that produces gluco-
steroids [24, 25]. The formation and dynamics of the fetal
zone, deﬁnitive zone, and transition zone form the fetal
adrenal cortex. In turn, the adrenal cortex can have long-
term eﬀects on the developing organism.
4. Embryogenesis and Development of the Fetal
AdrenalGland
Embryonic development of the fetal adrenal gland involves
cellular hyperplasia, hypertrophy, migration, and senescence
[4, 19]. As early as ﬁve weeks of gestation, the migration of
primitive cells accumulates at the cranial end of the meso-
nephros in what is called the “adrenal blastema” [19]. The
adrenal blastema, which is thought to be the ﬁrst identiﬁable
manifestation of the adrenal gland, exhibits mitotic activity,
suggesting that it develops by hyperplasia [4, 19, 26]. There-
after, neighboring primordial cells which are destined to
become steroidogenic cells are recruited to the adrenal blast-
ema [27]. Interestingly, these primordial cells are the same
cellsthatgiverisetosteroidogenicactivityinthegonads[27].
Ultimately the migration of primordial cells from the prim-
ordial mesoderm determines whether these cells will commit
to the adrenal gland or the gonads. Cells on the dorsal aortal
side of the primordial mesoderm give rise to steroidogenic
activity in the adrenal cortex, whereas those on the coelomic
epithelialsidemigratetowardsthegonads.Thecellscommit-
ted to the adrenal gland form a cord cluster with the adrenal
blastema. The cord cluster cells can then either diﬀerentiate
into large polyhedral cells that give rise to primordium of the
fetal zone or can maintain their small morphology and form
the deﬁnitive zone of the fetal adrenal cortex [4].
The large polyhedral cells have unique characteristics in-
cluding a larger number of tubular smooth endoplasmic re-
t i c u l a ,l a r g eG o l g ic o m p l e x e s ,a n dag r e a t e rn u m b e ro fm i t o -
chondriawithwell-deﬁnedcristae.Thesecellsarealsochara-
cterized by their high lipid production and abundance of
highly dense bodies [4]. These cellular properties are con-
sistent with characteristics of steroid-producing cells keeping
in agreement that the fetal zone is the primary site of stero-
idogenesis in the fetal adrenal gland [4]. The cells in the fetal
zone aside from having a unique structural composition are
arranged in a speciﬁc manner that optimizes the production
of DHEA-S. The cells in the central portion of the fetal zone
arearrangedfarapartina netlike patternwithmanyvascular
sinusoids, while the cells on the outer region of the fetal zone
are arranged in tightly packed cords [28]. This type of ar-
rangement is designed to speed up the transfer of molecules
through the cells and promotes steroidogenesis.
Comparative studies have shown that the cells in the de-
ﬁnitive zone are two to ﬁve times smaller than those in the
fetal zone. They are packed tightly together with small ribo-
somes, small dense mitochondria containing cristae, and a
poor lipid proﬁle [4]. Out of all these cellular characteristics
it is the poor lipid proﬁle that has the greatest biological ef-
fect as lipid composition modulates steroidogenic activity.
Cells with a lipid-rich proﬁle can produce steroidal com-
pounds, whereas those that have a lipid-poor proﬁle lack the
fundamental building blocks required for steroidogenesis.
The lipid-poor proﬁle in the deﬁnitive zone of the adrenal
gland is observed only in the ﬁrst half of pregnancy. At mid-
gestation, the deﬁnitive zone synthesizes aldosterone, a chol-
esterol byproduct, and thus, its cellular lipid proﬁle improves
around this time [28].
Another unique property of the deﬁnitive zone is its mit-
otic activity. By 10–12 weeks of gestation, the deﬁnitive zone
exhibits many mitotic subunits [19]. Thus, the deﬁnitive
zone grows mainly by hyperplasia, whereas the fetal zone
growsbyhypertrophy[18,19].Therapidcellproliferationin
thedeﬁnitivezonecausesmitoticpressureintheperipheryof
the adrenal cortex leading to centripetal migration of cells to
thefetalzone[19,20].WorkbyMorleyetal.[29]showedthat
in a mouse embryo the centripetal invasion of cells is only
established in the later stages of the fetal life when the lipid
composition of cells is improved. This centripetal migration
lends support to the migration theory of the adrenal cortical
cytogenesis and suggests that the deﬁnitive zone is the stem
cell compartment from which the inner cortical zones are
developed [4]. It is hypothesized that soon after birth, the
fetalzonedisappearsduetoincreasedapoptosisinthisregion
andthecentripetalmigrationofcellsfromthedeﬁnitivezone
drives the development of zona glomerulosa and fasciculate
[19, 30].
The adrenal medulla which is composed of hormone-
producing chromaﬃn cells does not exist as a discrete struc-
ture throughout gestation. Instead it is composed of small is-
lands of chromaﬃn cells that in the ﬁrst few weeks of gest-
ation are scattered throughout the fetal adrenal cortex but
then aggregate in the fetal zone. The disappearance of the fe-
tal zone at the beginning of postnatal life stimulates the
already aggregated chromaﬃn elements around the central
vein to form elementary medulla. This elementary medulla
undergoes extensive remodeling, and by the fourth week of
postnatal life, almost all of the chromaﬃn cells are clustered
in the central region of the adrenal gland. However, it is not
until one to two years postpartum that the morphological
development of the adrenal medulla resembles its adult
counterpart [4]. Further research is needed to determine
whether disruption of fetal adrenal cortex has an eﬀect on
the development and function of the adrenal medulla.
The development of the fetal adrenal gland is a well-
orchestratedphenomenonthatrequirestightregulation.Sig-
niﬁcant progress has been made in elucidating the role of
steroidogenic enzymes and nuclear receptors, fetal and ma-
ternal hypothalamic-adrenal function, and placental estro-
gens on fetal adrenal function, growth, and development.
5. The Role of Steroidogenic Enzymes and
Nuclear Receptors in Differentiation of
Cortical Zone Function
Thesteroidogenicpotentialoffetalcorticalzonesdependson
itssteroidogenicenzymesandnuclearreceptors.Thetwopri-
mary steroidogenic enzymes of the fetal adrenal gland are
P450c17 and 3β-HSD [4, 23]. Findings from immunohisto-
chemistry have revealed that P450c17 enzyme is expressed in
the fetal zone, 3β-HSD is expressed in the deﬁnitive zone,J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m 5
and that both enzymes are expressed in the transition zone
[4, 31]. These patterns of enzyme expression provide critical
clues regarding the steroidogenic role of each fetal adrenal
zone. The P450c17 enzyme stimulates DHEA-S production,
the 3β-HSD enzyme drives aldosterone production, and the
combinedeﬀectsofbothenzymesareresponsibleforcortisol
synthesis [4]. Based on this evidence and on the in situ pat-
terns of cholesterol cleavage, it has been determined that the
fetal zone, deﬁnitive zone, and transition zone are sites of
DHEA-S,aldosterone,andcortisolsynthesis,respectively[4].
For most of human pregnancy, the fetal adrenal cortex lacks
the 3β-HSD enzyme inhibiting its cortisol and/or aldoster-
one production. Therefore, the cholesterol substrate is used
primarilyforDHEA-Sproduction,makingittheprimaryby-
product of the fetal adrenal gland during gestation [32, 33].
According to human experiments, radiolabeled DHEA-S
can be converted to estradiol when perfused through the
placenta[34].Humanplacentaproducesestrogenbythearo-
matization of DHEA and its 16α-hydroxylated metabolite
(16α-OH DHEA) that is produced by the combined eﬀorts
of the adrenal cortex and the liver [4, 35]. In the placenta,
3β-HSD converts DHEA to androstenedione. Thereafter, the
androstenedione can either be converted to estrone by an
aromatase enzyme or to testosterone by 17β-hydroxysteroid
dehydrogenase (17β-HSD). The newly synthesized estrone
and/or testosterone can be further converted to estradiol by
17β-HSD or aromatase enzyme, respectively (Figure 1).
6. TheRelationshipbetweenFetalandMaternal
Hypothalamic-AdrenalFunction
The ongoing interaction between the fetus and the mother
has been the focus of many studies as scientists strive to un-
derstand the factors responsible for maintaining pregnancy
and stimulating labor and delivery. The essential and univer-
sal component of pregnancy is the endocrine communica-
tion between the mother and the fetus which greatly depends
on the maternal and fetal adrenal cortex. To understand the
speciﬁcroleoffetalandmaternaladrenalglandfunctiondur-
ing gestation, two adrenoectomized models have been devel-
oped:thematernaladrenalectomymodelandthefetoectomy
model. In the ﬁrst model, which is usually performed in rod-
ents, the adrenal glands are surgically removed from the
mother during gestation while the placenta and the fetus are
kept in situ. In the second model (i.e., fetoectomy), which is
typically performed in primates, the fetus is surgically re-
moved from the uterus and the placenta is kept in situ. The
use of these two experimental models has helped scientists
uncoversomeinformationabouttheinteractionbetweenthe
maternal and fetal adrenal gland function.
Studiesexaminingmaternaladrenalectomyhaverevealed
that the absence of maternal adrenal gland causes a substan-
tial reduction in plasma cortisol and estrogen levels. These
endocrine disruptions activate the fetal pituitary gland to
secrete adrenocorticotropic hormone (ACTH) [37–39]. Up-
regulation of ACTH promotes fetal production of corticos-
teroids (i.e., DHEA and DHEA-S) from the fetal adrenal
cortex, which serve as substrates for placental endocrine
production (Figure 3). Under these conditions, the fetus is
placed under stress and its fetal adrenal cortex takes over at
least part of the maternal adrenal function. In a study invest-
igating Sprague-Dawley rats, plasma DHEA-S levels of ad-
renalectomized dams rose from very low levels at 18 days of
gestationtolevelsthatweresubstantiallyhigherthanthoseof
sham rats on 21 days of gestation [40]. This ﬁnding suggests
that there is a critical factor that compensates for the lack of
maternal corticosteroid production. Based on the available
evidence, we suspect that the fetal adrenal cortex is the
primary modulator of these eﬀects. However, further studies
need to be conducted to support this hypothesis. Moreover,
research is required to determine whether maternal adrenal-
ectomy has long-term eﬀects on oﬀspring’s neuroendocrine
system that controls reaction to stress, digestion, immune
function, mood and emotion, sexuality, energy storage, and/
or expenditure.
The endocrine eﬀects of fetoectomy have only been pa-
rtially elucidated. Studies in baboons and rhesus monkeys
have shown that fetoectomy—a process where the fetus is re-
moved and the placenta is kept in situ—alters the maternal
hypothalamic-pituitary-adrenal axis [41–43], eliminates the
24-hour steroid rhythm [44], and causes a loss in uterine
activity [44]. Moreover, removal of the fetal adrenal gland
during late gestation has been shown to cause a signiﬁcant
reduction in maternal plasma ACTH levels and a concomi-
tant decrease in circulating cortisol and DHEA-S levels [41].
Interestingly, the drop in plasma DHEA-S concentrations
between intact and fetoectomized animals was roughly 35%
[41], which is equivalent to the diﬀerence between pregnant
and nonpregnant animals [45]. Under normal physiological
conditions, a drop in DHEA-S production is directly corre-
lated with a decline in maternal estradiol and progesterone
concentrations. This too was observed in fetoectomized ba-
boons [42, 46] and monkeys [41, 43, 44]. Reintroducing
DHEA-S to the placenta after fetoectomy was shown to re-
store placental estradiol production [46]. This data indicates
that fetoectomy does not modulate placental function but
rather that it aﬀects the production of DHEA substrates
needed by the placenta to generate endocrine hormones.
Thus, estrogen production in the maternal circulation is an
indicator of fetal adrenal steroidogenic activity. Taken to-
gether, this data strongly supports the idea that fetal adrenal
cortex plays a primary role in modulating the feto-maternal
endocrine communication.
7. Estrogen-MediatedEffectson Fetal
AdrenalFunction
The discovery that estrogen receptor alpha (ER-α)a n db e t a
(ER-β) are expressed in all zones of the fetal adrenal cortex
suggests estrogen has a direct eﬀect on fetal adrenal function.
By binding to ER-α and ER-β, estrogen can induce both
direct and indirect eﬀects on the fetal adrenal cortex, and
depending on plasma estrogen levels, it can stimulate or
inhibit its cellular responsivity to ACTH [36]. As depicted
in Figure 3, when high quantities of plasma estrogen are
reached, estrogen acts directly on the fetal adrenal cortex6 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
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Figure 3: Representation of how placental estrogen during gestation modulates its own production. Placental estrogen has a positive and
a negative feedback mechanism to ensure that physiological levels of estrogen are established. Estrogen produced by the placenta induces a
positive feedback mechanism by promoting the conversion of cortisol to its biologically inactive metabolite cortisone through upregulation
of 11β-HSD expression. Serum cortisone levels stimulate the fetal pituitary gland to produce ACTH which upregulates DHEA-S production
from the fetal adrenal cortical zone and leads to placental estrogen production. In contrast, if placental estrogen concentrations are too high,
placental estrogen can inhibit its own production by suppressing the responsiveness of the fetal adrenal zone to ACTH and lowering its
production of DHEA-S. This ﬁgure has been modiﬁed from Albrecht et al. [36].
to suppress its responsivity to ACTH activity. This inhibits
DHEA-Sproductionfromthefetalzoneoftheadrenalcortex
and thereby lowers placental estrogen synthesis [36, 47, 48].
Comparative real-time PCR studies have shown that ER-
α,E R - β mRNA, and protein expression is increased from
mid- to late gestation in the deﬁnitive and transitional zones
ofthefetaladrenalgland,butnotinthefetalzone[49,50].By
lowering the number of available ERs on the fetal zone of the
adrenal gland, the negative feedback system that suppresses
DHEA-S production is desensitized, the estrogen, mediated
positive feedback system is activated, and production of
DHEA-S is upregulated (Figure 3).
L o n g - t e r mc u l t u r e so fh u m a nf e t a la d r e n a lc e l l sh a v e
shown that estrogen binding to ER-α and ER-β can stimulate
DHEA-S production through an indirect pathway that sup-
presses cortisol synthesis [51]. Cortisol is a stress hormone
that maintains intrauterine homeostasis and inﬂuences the
development and maturation of many fetal tissues including
the lungs, liver, intestine, and the central nervous system
[52]. Too much cortisol during pregnancy may have an ad-
verse eﬀect on fetal development by increasing maternal
stress and blood pressure [52]. To protect the fetus from too
much cortisol, the placental enzymes, 11β-hydroxysteroid
dehydrogenase (11β-HSD), convert cortisol to the biologi-
cally inactive steroid, cortisone [4, 36, 53, 54]. This placental
enzyme is regulated by estrogen and progesterone [55]. An
increase in either estrogen or progesterone stimulates 11β-
HSD to increase transplacental oxidation of cortisol to cor-
tisone [55]. Low cortisol levels stimulate secretion of ACTH
bythefetalpituitarygland,whichinturnstimulatesDHEA-S
production from the fetal cortical zone, providing more
substrate for placental estrogen production. In cases where
ACTH levels become too high, the estrogen feedback loop
maybeturnedoﬀbystimulatingcortisolsynthesis(Figure 3)
[36].
In late gestation, ACTH receptor mRNA expression is
higher in the deﬁnitive and transitional zones than in the
fetal zone of the human fetal adrenal cells. This suggests that
ACTH promotes cortisol production during late gestation.
Cortisol can inhibit estrogen synthesis by suppressing ACTH
activity from the fetal pituitary gland. However, in late ges-
tation, this pathway is likely not activated because high
amounts of estrogen are required for initiation of parturi-
tion. Instead, high plasma cortisol levels in late gestation are
likely converted to cortisone through the estrogen-mediated
positive feedback system (Figure 3).
The available data has provided much mechanistic in-
sight regarding the role of estrogen in modulating the de-
velopment and function of fetal adrenal cortex [4, 36]. How-
ever, to more fully understand the role of estrogen in the fetal
adrenal gland, it is important to better characterize the ex-
pression of coactivators and corepressors as well as the pat-
tern of ER heterodimerization in diﬀerent regions of the
fetal adrenal gland. Moreover, three estrogen isoforms have
been identiﬁed but the precise role of these isoforms in the
physiology of pregnancy has not been elucidated. This may
be one of the limiting factors in our current understanding
of estrogen and fetal adrenal development. It is possible that
structural diﬀerences between the three estrogen isoforms
s e r v et oi n d u c es e l e c t i v ee ﬀects at the level of nuclear recep-
tor. Future research in this area will need to decipher the role
of estradiol, estrone, and estriol on adrenal gland develop-
ment and function.J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m 7
8. Estrogen-MediatedEffects on Fetal Adrenal
Growth and Development
Only one study has examined the eﬀects of plasma estrogen
levels on developmental diﬀerentiation of fetal cortical zones
[11]. In this paper, fetal adrenal glands were obtained from
baboons that had normal plasma estrogen levels and from
those that had abnormally low estrogen levels due to admin-
istration of a highly speciﬁc aromatase inhibitor. Findings
from this study revealed that fetal adrenal weight and vol-
ume increased 3-fold between mid- and late gestation and an
additional 70% by aromatase administration, which decreas-
edserumestradiollevelsby95%.The70%riseinfetaladren-
al growth among estrogen-deprived baboons was explained
by a signiﬁcant increase in the fetal zone. It was the only ad-
renal cortical site that exhibited any change in weight. This is
an interesting ﬁnding because although ER-α and ER-β are
expressed in all zones of the fetal adrenal cortex [36], loss of
estrogen had a selective eﬀect on the fetal zone, the primary
site of stereocorticoid production. The observed increase in
fetal zone size among estrogen-deprived baboons was asso-
ciated with a 3-fold rise in fetal serum DHEA-S levels. Based
on this evidence, researchers from this study concluded that
plasma estrogen concentrations selectively repress both the
morphological and functional development of the fetal zone
in utero between mid- and late gestation [11]. According to
these ﬁndings, it is possible that estrogen produced by the
placentafeedsbacktothefetalzoneofthefetaladrenalcortex
to restrain its growth and development. By controlling the
size of the fetal zone, estrogen may be able to regulate the
amount of DHEA-S being produced and, in turn, its own
production. This is important because having high levels of
estrogen can lead to endocrine disruption that may have de-
leterious eﬀects on fetal growth and maturation [56].
9. Does Exposure to Environmental Estrogens
Affect the Fetal Adrenal Gland Development
andFunction?
Exposure to environmental estrogens during perinatal life
may have permanent long-lasting consequences on the over-
all growth and development of the fetus [56] .T h ef e t u sh a sa
faster metabolic rate, a weaker immune system, and a lower
concentration of detoxifying enzymes and liver metabolites
compared to an adult, making it more sensitive to environ-
mentaldisruptions[57].Moreover,duetoitssmallbodysize,
exposure to environmental estrogens may cause chemical
toxicity in the fetus at a concentration that has no adverse
eﬀe c ti na na d u l t[ 57]. A growing number of commercially
available products containing low doses of estrogen also
increase the risk of estrogen accumulation in the mother as
well as the fetus. Fetal cells are highly susceptible to change,
so exposure to environmental estrogens, powerful chemical
messengers, may induce adverse eﬀects on fetal growth,
development, and future health.
Although there are many environmental estrogens in the
world today, their eﬀects on fetal programming as well as fe-
tal adrenal gland development and function have not been
extensively studied. One exception is DES, a synthetic estro-
gen that used to be administered to pregnant women for pre-
vention of miscarriages from the mid-1940s to 1970s [58–
60]. Its use was discontinued, after several million oﬀspring
were exposed, because it was discovered that in utero expos-
ure to DES causes major developmental changes in the of-
fspring.Itdisruptsreproductivetractdevelopmentandfunc-
tionatsexualmaturityin30%oftheexposedpopulation[61,
62]. Female oﬀspring exhibit reduced fertility and signiﬁcant
increase in vaginal carcinomas, while male oﬀspring suﬀer
from reduced testicular size and sperm count [57]. Both gen-
ders,whenexposedtoDESduringprenataldevelopment,are
susceptible to benign tumors in reproductive organs and
autoimmune disorders [57]. Therefore, developmental cha-
nges induced by in utero exposure to DES have long-term
programming eﬀects on reproductive function. As previ-
ouslymentioned,theprimordialcellsthatgiverisetoreprod-
uctive organs are the same cells that give rise to the fetal zone
of the fetal adrenal gland [4] (see Section 4), suggesting that
prenatal exposure to DES may also disrupt adrenal gland
development and function. Female rats treated with DES
from gestation day 8 to 18 had a 30% enlargement in adrenal
glandweightandasigniﬁcantlylowerconcentrationofcircu-
lating adrenal steroid hormones compared to the control
group, including a 60% and 32% reduction in serum proges-
terone and estrogen levels, respectively [63] .T h ee x p o s u r et o
DES was also shown to reduce uterine contractions, prevent
placental detachment from the uterine wall, and increase
fetal death.
In examining fetal survival, it appears that the rat fetus
is the most sensitive to DES treatment when exposure occurs
between 18 and 20 days of gestation [63], suggesting that ex-
posure to environmental estrogens has the most profound
eﬀect on fetal development in late gestation. This is not sur-
prisingbecauseDESisstructurallysimilartoestradioland,as
such, can bind to ERs to induce estrogen-like eﬀects [64, 65].
Exposure to exogenous estrogens during late gestation has
the potential to activate the negative feedback loop to inhibit
DHEA-S production from the fetal adrenal cortex because
the fetus is already exposed to high levels of endogenous
estrogen. Moreover, such high levels of estrogen could cause
a decrease in blood gonadotropins (i.e., FSH, LH) which in
turn could slow down follicular development and depress
follicular synthesis of progesterone and testosterone [66–68].
The aromatase enzyme converts testosterone to estradiol,
andthus,thispathwaymayalsobeturnedoﬀ[69].Depressed
fetalzonefunctionanddecreasedfollicularsynthesisoftesto-
sterone may in combination suppress de novo synthesis of
estrogen. As shown by Zimmerman et al. [63] dams treated
with DES had a 60% and 32% reduction in progesterone and
estrogen levels, respectively, compared to the control group.
DESisnolongeradministeredclinicallyforpreventionof
miscarriages but remains a useful compound for investigat-
ing the role of estrogen on fetal growth and development
[70, 71]. Findings from DES studies are currently being used
to better characterize the biological eﬀects of other estro-
genic compounds, including dietary estrogens [70–72]a n d
BPA. The most commonly studied dietary estrogens during
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in soy-based foods such as soy milk, tofu, miso, and soy pro-
tein [73]. Traditional Asian diets are rich in soy-based foods,
and thus, many Asian populations consume between 15 and
40mg of isoﬂavones a day [74–77]. At this level of exposure,
there is no evidence that soy-based foods or isoﬂavones have
adverse eﬀects on human health. However, there are sub-
stantial diﬀerences in the form (fermented versus nonfer-
mented), dose, and timing of isoﬂavone exposure between
the traditional Asian and current Western diets [78]. Soy-
beans used for production of soy-based foods undergo some
type of processing. Soybeans used in traditional Asian diets
undergo germination, cooking, roasting, and fermentation
while those used in Western diets employ more modern
methods such as fractionation and extraction. The diﬀer-
ences in soybean processing can aﬀect the bioavailability of
isoﬂavones and digestibility of soy protein through removal
of indigestible sugars and inactivation of enzymes [79].
Studies show that fermented soy foods (i.e., miso and
tempeh) are rich in aglycones that are more bioactive than
the glycone form of isoﬂavones [79]. However, many unfer-
mented soy foods available on the Western market can con-
tain a substantially higher amount of total isoﬂavones (agly-
cone and glycone forms of isoﬂavone). For example, one soy
burger contains 15–25mg of isoﬂavones. A soy protein bar,
often marketed as a meal replacement bar and sometimes
used in weight management strategies, can contain 60mg of
isoﬂavones per serving. Consuming three to four servings of
these soy foods a day in the Western World can exceed the
level of isoﬂavone exposure reported in Asian populations
(100–200mg/day versus 15–40mg/day). It is also possible
that North Americans respond diﬀerently to soy foods than
Asian populations because of their diﬀerence in timing of
isoﬂavone exposure. Asian populations consume soy foods
throughout their entire life, except for the brief neonatal
period when most infants are breastfed [80, 81]. In contrast,
in North America, soy is primarily consumed by infants fed
soy protein formula or by health conscious adults eating a
plant-based diet for general health and/or lowering risk of
developing a chronic disease such as heart disease. Pregnant
women consuming soy foods expose their fetus to isoﬂav-
ones. Studies show that isoﬂavones are transferred readily
across the placenta in humans and rodent models [82, 83].
Cord serum concentrations of genistein, daidzein, and equol
correlate closely with maternal serum concentrations and
isoﬂavones remain longer in fetal than maternal circulation
[84]. Thus, depending on maternal diet, there is potential for
a fetus to be exposed to substantial levels of isoﬂavones in
utero.
The spatial and structural arrangement of isoﬂavones is
slightly diﬀerent from that of estrogen, and thus, they can
induce both estrogenic and nonestrogenic eﬀects. Findings
from two studies suggest that soy isoﬂavones may be able to
alter fetal adrenocortical function [85, 86]. Feeding daidzein
to late pregnant sows downregulates ER-β expression in the
hypothalamus, which likely aﬀects the regulation of fetal
zone DHEA-S production [85]. In cultured human fetal ad-
renocortical cells, soy isoﬂavones (i.e., genistein and dai-
dzein) decrease ACTH-stimulated cortisol production by in-
hibiting the expression of 21-hydroxylase (P450c21) but had
noeﬀectonDHEA-Sproduction[86].Furtherresearchisre-
quired to elucidate whether in utero exposure to soy isoﬂav-
one can alter DHEA-S production in vivo and whether there
are other eﬀects that may be subtle but nonetheless have life-
long implications to health.
10. The Effects of EnvironmentalEstrogen on
Fetal Adrenal Cortex May Be Mediated
through Epigenetic Changes
Although not fully understood, it has been hypothesized that
estrogenic compounds during perinatal life can modulate
epigenetic gene regulation, resulting in permanent eﬀects
that alter responses in later life and transgenerational inher-
itance. The most commonly studied epigenetic modiﬁcation
isDNAmethylation,usedbymammalstoregulategenetran-
scription, chromosomal positioning, activation of X-chrom-
osome, and gene imprinting. From a molecular perspective,
DNA methylation is a term used to denote the attachment
or substitution of a methyl group for a hydrogen atom on
a cytosine residue. In vertebrates, DNA methylation depends
on an enzyme known as methyltransferase which recognizes
the CpG dinucleotides of various palindromic sequences and
then catalyzes the transfer of the methyl group on the
cytosineresidue.Asaresult,modulatorsofDNAmethylation
are typically methyl donors or acceptors. However, estrogen-
based compounds, which have been postulated to play a role
in DNA methylation, cannot donate or accept a methyl
group. Instead, it is believed that estrogenic compounds are
able to enhance histone acetylation through interaction with
ERs and that this interaction may open up the methylation
region [87]. When this happens, methyl donors and cofac-
tors including folate, choline, and SAM may stimulate DNA
methylation [88].
F e t u s e sa r ee x p o s e dt oh i g hc o n c e n t r a t i o n so ff o l a t ed u r -
ing early stages of development because mothers are advised
to consume folate supplements during pregnancy to lower
the incidence of spina biﬁda [89–91]. As a result, the com-
bination of folic acid with high concentrations of circulating
estrogens during early stages of development may cause an
additiveorsynergisticeﬀectonDNAmethylation[88].These
changes in DNA methylation patterns have the potential to
induce both beneﬁcial and adverse eﬀects on the developing
genome.Futureresearchisrequiredtoconﬁrmwhetherearly
exposure to environmental estrogens can alter the plasma
estrogen proﬁle enough to induce long-term programming
eﬀect on the developing fetus.
To date, only one study has investigated whether soy iso-
ﬂavones can alter DNA methylation patterns [88]. This study
found that exposure to genistein resulted in hypermethyla-
tion of six CpG sites in the agouti mouse genome, which de-
creased the incidence of adult-onset obesity. ER-α, which has
been shown to play a role in adrenal gland development and
function, has at least eight promoters that contain CpG
islands and are thus tightly regulated by DNA methylation
[92]. Thus, it is possible that by regulating DNA methylation
isoﬂavones as well as other environmental estrogens may be
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11. Conclusion
The fetal adrenal cortex, together with the placenta and the
maternal adrenal cortex, forms a unique fetomaternal endo-
crine system that regulates estrogen production during de-
velopment. To date, notable progress has been made in un-
derstanding the embryogenesis and morphology of the fetal
adrenal gland, the role of steroidogenic enzymes and nuclear
receptors in diﬀerentiation of cortical zone function, and the
process by which estrogen regulates its own production in
the fetal adrenal cortex. However, there is still much work
tobedoneincharacterizingtheeﬀectsofinuteroexposureto
environmental estrogens on fetal adrenal gland development
and function. The available evidence suggests that exposure
to environmental estrogens such as DES and soy isoﬂavones
can reduce cortisol and DHEA synthesis in the fetal adrenal
cortex as well as decrease placental estrogen production. The
decrease in placental estrogen production during sensitive
stages of development has the potential to alter gene trans-
cription and DNA methylation patters of cells, suggesting
that environmental estrogens may be able to induce epige-
netic changes in the developing fetus.
Future studies on this topic should examine whether ex-
posure to environmental estrogens can provide a causal me-
chanism to explain some of the endocrine-mediated adult-
onset diseases. By integrating current knowledge of develop-
mental biology with concepts of endocrine regulation, fu-
ture studies will be better directed into uncovering the dis
ruptions induced by environmental estrogens on fetal adre
nal gland development and function.
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